Aluminium

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Aluminium
   1. Pharmacist Assessment Report
   2. Aluminium: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Aluminium: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Aluminium, so there is currently no new predicted indication. No recorded uses are listed for this drug, so each group below is empty.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	—

Related to an approved indication (same disease category)

Indication	Approved category
none	—

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
7642F	nan	nan	Valid

Safety Considerations

• Aluminium accumulation: Volunteer data show aluminium can accumulate in liver tissue and cerebrospinal fluid with short-course anti-ulcer therapy, and serum aluminium changes have been reported with sucralfate.
• Renal impairment: Reduced elimination may increase aluminium exposure in patients with impaired kidney function.
• Neurological signal: An epidemiological study examined dementia mortality in gastroduodenal ulcer patients with high aluminium-antacid intake. This is a safety signal, not proof of harm.

No drug interactions were identified in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---